PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
22 févr. 2018 07h00 HE
|
Provectus Biopharmaceuticals Inc.
Current Phase 1 basket study continues to enroll and treat patients for HCC and liver cancer metastases (colorectal, lung, pancreatic, melanoma, ovarian, and breast); updated data presentation planned...
FIRST STUDY OF QUALITY OF LIFE OF PATIENTS WITH LOCALLY ADVANCED CUTANEOUS MELANOMA PUBLISHED IN MELANOMA RESEARCH
27 déc. 2017 16h00 HE
|
Provectus Biopharmaceuticals Inc.
Emotional health/self-perception issues were most common; limitations of lifestyle and activities as well as coping strategies were also important Provectus Biopharmaceuticals expands pivotal Phase 3...
PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE
14 déc. 2017 06h00 HE
|
Provectus Biopharmaceuticals Inc.
– Protection expands coverage for combinations of intralesional PV-10 with checkpoint inhibitors for multiple solid tumor cancers – KNOXVILLE, TN, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Provectus...
PROVECTUS Announces Resolution of SEC Investigation
12 déc. 2017 16h33 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2017 (GLOBE NEWSWIRE) -- — Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage biotechnology company...
PROVECTUS Announces Resolution of SEC Investigation
12 déc. 2017 16h19 HE
|
Provectus Biopharmaceuticals Inc.
– SEC “takes into account the proactive remediation and cooperation by the [C]ompany’s new leadership” – – No monetary penalties; Commission notes actions already taken by Provectus to remedy...
PROVECTUS ANNOUNCES RESULTS FROM MECHANISM OF ACTION STUDY OF TOPICAL PH-10 FOR THE TREATMENT OF PSORIASIS
30 nov. 2017 06h00 HE
|
Provectus Biopharmaceuticals Inc.
– Responses mediated by multiple pathways, including IL-17, IL-22 and interferons – – Down-regulation of more than 500 disease-related genes; wide range of central “psoriasis-related” genes...
PROVECTUS BIOPHARMACEUTICALS RECEIVES SECOND CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE
07 nov. 2017 16h00 HE
|
Provectus Biopharmaceuticals Inc.
– Protection expands coverage for combinations of intralesional PV-10 with anti-PD-1 and anti-PD-L1 agents for melanoma and cancers of the liver – KNOXVILLE, TN, Nov. 07, 2017 (GLOBE NEWSWIRE)...
PROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMA
23 oct. 2017 08h00 HE
|
Provectus Biopharmaceuticals Inc.
– Key impacts comprised worry/concern, altered clothing choices, and limitations to physical functioning – – Study results further support the clinical significance of Provectus’ ongoing,...
PROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMA
18 oct. 2017 09h38 HE
|
Provectus Biopharmaceuticals Inc.
– Adverse events consistent with established patterns for each drug; no unexpected toxicities observed – 50% overall objective response rate; 10% complete response; highest responses observed in...